[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353540-105":59,"doc-detail-353540-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","beyond-tumor-mutation-burden-tumor-neoantigen-burden-as-a-superior-prognostic-biomarker-in-resected-gastric-cancer","Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer","","Gastric cancer remains a leading cause of cancer-related mortality. This study evaluates whether tumor neoantigen burden (TNB) can better predict clinical outcomes than tumor mutational burden (TMB) in patients undergoing gastric cancer resection. Whole-exome and transcriptome sequencing were performed on tumor tissues from 85 resected patients to assess the prognostic value of TMB and TNB in Chinese cohorts. Results show TNB significantly stratifies overall survival at early and late timepoints, accompanied by distinct pathway enrichment and higher neutrophil infiltration in the TNB-high group.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/beyond-tumor-mutation-burden-tumor-neoantigen-burden-as-a-superior-prognostic-biomarker-in-resected-gastric-cancer/353540/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/beyond-tumor-mutation-burden-tumor-neoantigen-burden-as-a-superior-prognostic-biomarker-in-resected-gastric-cancer/353540.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main aim of the study?","Question",{"text":112,"@type":113},"To evaluate the prognostic value of tumor neoantigen burden (TNB) for predicting clinical outcomes in patients undergoing resection for gastric cancer, and compare it with tumor mutation burden (TMB).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the prognostic analysis performed?",{"text":117,"@type":113},"Whole exome and transcriptome sequencing were conducted on tumor tissues from 85 resected gastric cancer patients, followed by evaluation of TMB and TNB prognostic performance in a Chinese cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show regarding TNB versus TMB?",{"text":121,"@type":113},"Unlike TMB, TNB achieved significant prediction of overall survival at both early and late follow-up timepoints, with expanded restricted mean survival time at 2 and 3 years.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353540,1790193757,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Original Research PUBLISHED 05 January 2026  \nDOI 10.3389/fimmu.2025.1722895  \nOPEN ACCESS  \nEDITED BY  \nGiulia Piaggio,  \nHospital Physiotherapy Institutes (IRCCS), Italy  \nREVIEWED BY  \nXiao-Peng Duan,  \nShanghai Changzheng Hospital, China Gennaro Ciliberto,  \nTakis S. R. L., Italy  \n*CORRESPONDENCE  \nJi Wan  \n[jiw@neocura.net](jiw@neocura.net)[ ](jiw@neocura.net)Hongqing Xi  \n [xihongqing301@163.com](xihongqing301@163.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 11 October 2025  \nREVISED 24 November 2025  \nACCEPTED 03 December 2025  \nPUBLISHED 05 January 2026  \nCITATION  \nLu T, Cao J, Liu P, Pan X, Shen Y, Wang J, Chen Z, Liu Y, Zhang F, Zhang H, Zhang G, Wang Y, Wan J and Xi H (2026) Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer.  \nFront. Immunol. 16:1722895 .  \ndoi: 10.3389/fimmu.2025.1722895  \nCOPYRIGHT  \n© 2026 Lu, Cao, Liu, Pan, Shen, Wang, Chen, Liu, Zhang, Zhang, Zhang, Wang, Wan and Xi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBeyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer  \nTingting Lu 1†, Jingyi Cao 2†, Peng Liu 2, Xiaoxin Pan 2, Yiming Shen 2, Jian Wang 2, Zhida Chen 1, Yi Liu 1, Fenglin Zhang 1, Haiya Zhang 1, Gan Zhang 1, Yi Wang 2, Ji Wan 2* and Hongqing Xi 1*  \n1 Department of General Surgery, The First Medical Center, Chinese People's Libration Army (PLA) General Hospital, Beijing, China, 2Shenzhen Neocurna Biotechnology Corporation, Shenzhen, China  \nIntroduction: Gastric cancer is one of the most diagnosed cancers and a major contributor to cancer-related death in China. Recent studies have demonstrated the failure of tumor mutational burden (TMB) in predictive accuracy. Here, we aimed to evaluate the prognostic value of tumor neoantigen burden (TNB) to predict the clinical outcome among patients undergoing gastric cancer resection. Methods: This study performs whole exome and transcriptome sequencing of tumor tissues of 85 gastric cancer patients who underwent resection surgery. The prognostic value of TMB and TNB in Chinese gastric cancer patients were evaluated, respectively.  \nResults: In contrast to TMB, TNB achieved signiﬁcance in predicting overall survival at both early (a median follow-up period of 23.5 month) and late (a median follow-up period of 35.5 month) timepoints (p-value\u003C0.05), particularly with expanding 2-year and 3-year restricted mean survival time (RMST) . According to the comparative enrichment and protein-protein interaction analysis of TNB-and TMB-associated genes, we found the upregulated TNBassociated genes were signiﬁcantly enriched in hormone and nutrient sensing cascades, whereas their counterparts were predominantly linked to cytoskeletal development. In addition, we also noticed an increased inﬁltration of neutrophils in TNB-High group (p-value=0 . 04) .  \nDiscussion: In summary, this study indicated that the prognosis of TNB-High patients was signiﬁcantly better than their counterparts, which might be associated with impaired energy metabolism.  \nKEYWORDS  \ngastric cancer, prognosis, next-generation sequencing, tumor neoantigen burden, tumor mutation burden  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nAs a major component of gastrointestinal cancer, stomach cancer has become the ﬁfth incidence and fourth in mortality worldwide. Especially in Asian countries, stomach cancer remains the top three most prevalent malignancy in China (1), with a","cbCaimz9ulA9H2TV","https://ap.wps.com/l/cbCaimz9ulA9H2TV","pdf",5726802,11,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What is the main aim of the study?\",\"answer\":\"To evaluate the prognostic value of tumor neoantigen burden (TNB) for predicting clinical outcomes in patients undergoing resection for gastric cancer, and compare it with tumor mutation burden (TMB).\"},{\"question\":\"How was the prognostic analysis performed?\",\"answer\":\"Whole exome and transcriptome sequencing were conducted on tumor tissues from 85 resected gastric cancer patients, followed by evaluation of TMB and TNB prognostic performance in a Chinese cohort.\"},{\"question\":\"What did the results show regarding TNB versus TMB?\",\"answer\":\"Unlike TMB, TNB achieved significant prediction of overall survival at both early and late follow-up timepoints, with expanded restricted mean survival time at 2 and 3 years.\"}]","Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer | PDF",1790105965,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7eab6ea243ee677f286e67d7970e3de3.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdf76cefbd0d6012009b5c0d0d269363.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85cc333ad999b734cea731c81bf937be.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84b4192900c394b8fa2d6e03f82a478a.webp",980,1385]